Citations 1
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Saad, Ayman , Loren, Alison W. , Bolaños‐Meade, Javier , Chen, George , Couriel, Daniel R. , Stasi, Antonio Di , El‐Jawahri, Areej , Elmariah, Hany , Gundabolu, Krishna , Gutman, Jonathan A. , Ho, Vincent T. , Hoeg, Rasmus T. , Horwitz, Mitchell E. , Hsu, Joe L. , Dabaja, Mohamed Kharfan, Magenau, John, Martin, Thomas , Moreira, Jonathan , Nakamura, Ryotaro , Ninos, Cameron , Oliai, Caspian , Patel, Seema M., Randolph, Brion, Tzachanis, Dimitrios , Varshavsky‐Yanovsky, Asya, Vusirikala, Madhuri , Algieri, Frankie, Pluchino, Lenora A. , Kharfan Dabaja, Mohamed, Saad, Ayman , Elmariah, Hany , Farag, Sherif Shafik , Kassim, Adetola A , Mielcarek, Marco B. , Nieto, Yago , Oliai, Caspian H , Schroeder, Mark A.
Journal of the National Comprehensive Cancer Network | February 15, 2023 | Volume: 21 | Issue: 2 | Pages: 108-115
The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.